NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES
April 09, 2019 02:16 ET
|
Nanobiotix S.A.
NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES Funds raised through an accelerated bookbuild offering announced on April 8, 2019 Placement follows...
NANOBIOTIX LANCE UNE AUGMENTATION DE CAPITAL PAR CONSTRUCTION ACCELEREE D’UN LIVRE D’ORDRE
April 08, 2019 12:20 ET
|
NANOBIOTIX
NANOBIOTIX LANCE UNE AUGMENTATION DE CAPITAL PAR CONSTRUCTION ACCELEREE D’UN LIVRE D’ORDRE Paris, France, 8 avril 2019 – NANOBIOTIX (la « Société ») (Euronext: NANO – ISIN: FR0011341205), société...
NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING
April 08, 2019 12:20 ET
|
NANOBIOTIX
NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING Paris, France, April 8, 2019 – NANOBIOTIX (the “Company”) (Euronext: NANO – ISIN: FR0011341205), a...
RefleXion to Unveil New Approach to Cancer Treatment at ASTRO
October 18, 2018 09:00 ET
|
RefleXion Medical
Biology-guided Radiotherapy May Improve Physician Confidence in Treatment of Multiple Tumors HAYWARD, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- RefleXion Medical, a biotargeting oncology company...
Nanobiotix présentera les résultats positifs de son étude de phase II/III évaluant NBTXR3 dans les Sarcomes Des Tissus Mous (STM) et de ses autres études de phase I/II aux prochains congrès annuels de l’ESMO et de l’ASTRO
September 26, 2018 02:00 ET
|
NANOBIOTIX
NANOBIOTIX PRESENTERA LES RESULTATS POSITIFS DE SON ETUDE DE PHASE II/III EVALUANT NBTXR3 DANS LES SARCOMES DES TISSUS MOUS (STM) ET DE SES AUTRES ETUDES DE PHASE I/II AUX PROCHAINS CONGRES...
Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual conferences
September 26, 2018 02:00 ET
|
NANOBIOTIX
NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND ASTRO...
RefleXion Medical Raises $100 Million Series C to Commercialize Revolutionary Cancer Treatment
April 04, 2018 03:01 ET
|
RefleXion Medical
HAYWARD, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- RefleXion Medical, a medical technology company developing the first and only biology-guided radiotherapy system (BgRT) for targeted cancer...
Alpha Tau Medical Initiates First Clinical Trial in Italy to Treat Cancer with Alpha Radiation
October 30, 2017 07:30 ET
|
Alpha Tau Medical LTD.
TEL AVIV, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical is happy to announce its first clinical trial in Italy. The study at IRST, Meldola, will evaluate the feasibility, safety and...
Market for Radiotherapy Technologies to Be Worth $9.2B by 2022
August 14, 2017 05:00 ET
|
BCC Research
WELLESLEY, Mass., Aug. 14, 2017 (GLOBE NEWSWIRE) -- A strong trend toward using adjunct radiotherapy in combination with other approaches, combined with its well-established use in cancer, is...
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
October 20, 2016 02:30 ET
|
RadioMedix Inc.
Houston, TX, Oct. 20, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston,TX) is excited to announce the completion of the Phase I/II clinical trial of AminoMedix ™ proprietary formulation used...